Find Funding Opportunities

Find Funding Opportunities

Returning 24 results

Notice of Special Interest for HEAL Initiative: Request for Administrative Supplements to Existing Grants for Identification and Validation of New Pain and Opioid Use Disorder Targets within the Understudied Druggable Genome

Notice of Special Interest
Tuesday, March 10, 2020
Tuesday, June 2, 2020
333
NOT-TR-20-008

Funding Opportunity Purpose

Notice Special Interest HEAL Initiative: Request Administrative Supplements Existing Grants Identification Validation New Pain Opioid Disorder Targets within Understudied Druggable Genome Notice Number: NOT-TR-20-008 Key Dates Release Date: March 9, 2020 First Available Due Date: March 17, 2020 Expiration Date: June 02, 2020 Related Announcements PA-18-591 Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) Issued National Center Advancing Translational Sciences NCATS) National Institute Dental Craniofacial Research NIDCR) National Institute Drug Abuse NIDA) National Institute Neurological Disorders Stroke NINDS) National Center Complementary Integrative Health NCCIH) National Institute Arthritis Musculoskeletal Skin Diseases ( NIAMS ) - New participating organization of March 26, 2020 due dates on/after June 01, 2020 Purpose Notice part the NIH Helping End Addiction Long-Term HEAL) Initiative, aggressive, trans-agency effort speed scientific solutions stem national opioid public health crisis. NCATS other participating institutes Centers ICs) inviting investigators relevant active research project grants cooperative agreements submit administrative supplements, according to PA-18-591 Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional), funded projects identify validate new pain opioid disorder OUD) targets within understudied Druggable Genome. Background: human genome revealed great deal the human proteome, though significant portions the genome remain understudied. Only subset expressed proteins demonstrate requisite properties serve targets the development therapeutics. bona fide drug targets likely remain be discovered the Druggable Genome” DG), can defined a subset the 20,000 protein-coding genes the human genome have potential bind drug-like molecules. term drug-like" refers the physical, biochemical, pharmacological attributes small molecule compounds are generally recognized be required efficacious clinical drugs humans. While number proteins the DG upwards 4,500, existing clinical pharmacopeia represented only few hundred targets, leaving huge swath biology remains unexploited. announcement for one-year administrative supplements ongoing funded projects support research will identify validate new targets pain OUD among understudied proteins the Druggable Genome. Kinases such ERK1/2, p38 JNK been shown counteract opioid analgesia precede desensitization the opioid receptors. addition, opioid receptors belong the well-known Gi/o class GPCRs, GPCRs been shown mediate pain neurogenic inflammation. Finally, ion channels been identified critical elements pain signaling transmission. these families contain adequate numbers understudied members are well established druggable families shown be critical pathways associated pain OUD, experimental focus be placed understudied members the families non-olfactory GPCRs, ion channels protein kinases. Eligible understudied proteins listed below considered understudied, they meet following criteria: protein 1) a low number publications/citations, a Jensen Pubmed score Understudied proteins eligible research support under notice: Kinases ADCK1, ADCK2, ADCK5, ALPK2, ALPK3, BCKDK, BRSK1, CAMK1D, CAMK1G, CAMKK1, CAMKV, CDC42BPA, CDC42BPB, CDC42BPG, CDK10, CDK11A, CDK11B, CDK12, CDK13, CDK14, CDK15, CDK16, CDK17, CDK18, CDK19, CDK20, CDKL1, CDKL2, CDKL3, CDKL4, CLK3, CLK4, COQ8A, COQ8B, CSNK1A1L, CSNK1G1, CSNK1G2, CSNK1G3, CSNK2A3, DCLK3, DSTYK, DYRK1B, DYRK2, DYRK3, DYRK4, EEF2K, ERN2, HIPK1, HIPK3, HIPK4, ICK, LMTK2, LMTK3, LRRK1, LTK, MAP3K10, MAP3K14, MAP3K15, MAP3K21, MAPK15, MAPK4, MARK1, MARK3, MARK4, MAST2, MAST3, MAST4, MKNK2, NEK1, NEK10, NEK11, NEK3, NEK4, NEK5, NEK6, NEK7, NEK9, NIM1K, NRBP2, NRK, NUAK2, PAK3, PAK5, PAK6, PAN3, PDIK1L, PHKG1, PHKG2, PI4KA, PIK3C2B, PIK3C2G, PIP4K2C, PIP5K1A, PIP5K1B, PIP5K1C, PKMYT1, PKN3, PNCK, POMK, PRKACB, PRKACG, PRPF4B, PSKH1, PSKH2, PXK, RIOK1, RIOK2, RIOK3, RPS6KC1, RPS6KL1, SBK2, SBK3, SCYL2, SCYL3, SGK494, SRPK3, STK17A, STK17B, STK19, STK3, STK31, STK32A, STK32B, STK32C, STK33, STK36, STK38L, STK40, STKLD1, TAOK1, TAOK2, TBCK, TESK1, TESK2, TLK1, TLK2, TP53RK, TSSK1B, TSSK2, TSSK3, TSSK4, TSSK6, TTBK1, TTBK2, ULK4, VRK2, VRK3, WEE2, WNK2, WNK3 Ion Channels ASIC4, BEST4, CACNA2D2, CACNA2D3, CACNA2D4, CACNG1, CACNG3, CACNG4, CACNG5, CACNG6, CACNG7, CACNG8, CALHM4, CALHM5, CALHM6, CATSPER2, CHRNA10, CHRNB1, CLCA4, CLCC1, CLCN6, CLIC6, GABRP, GPR89A, GPR89B, GRID1, KCNA6, KCNA7, KCNAB2, KCNAB3, KCND1, KCNG2, KCNG3, KCNG4, KCNH4, KCNH6, KCNH8, KCNJ15, KCNJ18, KCNK12, KCNK7, KCNMB3, KCNN1, KCNS1, KCNS2, LRRC38, LRRC55, PKD1L2, PKD1L3, PKD2L2, PLLP, SCN7A, SLC26A1, TMC3, TMC4, TMC5, TMC7, TMEM38B, TMEM63A, TMEM63B, TTYH1, TTYH2 G-Protein Coupled Receptors GPCRs) ADGRA1, ADGRA3, ADGRB2, ADGRB3, ADGRD1, ADGRD2, ADGRE1, ADGRE3, ADGRF1, ADGRF2, ADGRF3, ADGRF4, ADGRF5, ADGRG2, ADGRG3, ADGRG4, ADGRG5, ADGRG7, FZD10, GNRHR2, GPR101, GPR12, GPR135, GPR137, GPR139, GPR141, GPR142, GPR146, GPR149, GPR150, GPR151, GPR152, GPR153, GPR156, GPR157, GPR160, GPR162, GPR171, GPR173, GPR174, GPR18, GPR19, GPR20, GPR21, GPR22, GPR25, GPR26, GPR27, GPR3, GPR31, GPR32, GPR34, GPR37L1, GPR4, GPR45, GPR52, GPR6, GPR61, GPR62, GPR63, GPR65, GPR68, GPR75, GPR78, GPR82, GPR85, GPR87, GPR88, GPRC5A, GPRC5B, GPRC5C, GPRC5D, HCAR1, HCAR3, LPAR6, MRGPRE, MRGPRF, MRGPRG, MRGPRX1, MRGPRX2, MRGPRX3, MRGPRX4, NPBWR1, NPBWR2, OXER1, OXGR1, P2RY10, PROKR1, QRFPR, RXFP4, TAAR2, TAAR3P, TAAR8, TAAR9, TAS2R1, TAS2R10, TAS2R13, TAS2R14, TAS2R16, TAS2R19, TAS2R20, TAS2R3, TAS2R30, TAS2R31, TAS2R39, TAS2R4, TAS2R40, TAS2R41, TAS2R42, TAS2R43, TAS2R46, TAS2R5, TAS2R50, TAS2R60, TAS2R7, TAS2R8, TAS2R9 Examples potential research areas include would be limited to: Isolation purification understudied proteins and in vitro/in vivo characterization the intent developing novel therapeutics; Validation placement understudied protein(s) signaling cascades, including upstream signals downstream activities order better understand pain OUD targets; Pre-clinical animal studies understudied Druggable Genome candidate proteins focused therapeutic development development candidate therapeutics; Characterization cell- tissue-specific protein expression, localization, function understudied protein(s) native environments they pertain pain OUD; of novel tools validate preliminary disease physiological associations understudied proteins animal models, biomimetic systems, or ex vivo human samples; Studies establish preliminary structure-activity-relationships SAR) between functions an understudied protein its ligands e.g., small molecules, macrocycles, synthetic peptides) future drug discovery projects. work proposed must within scope the existing award. Before submitting supplement request, principal investigators strongly encouraged contact appropriate IC contact listed the end this notice any questions to discuss whether proposed supplement within scope the parent award consistent the priorities the IC supporting parent award. Applications must include detailed description the proposed activities a justification the proposed work within scope the existing award. Sufficient justification should provided indicate why particular protein(s) chosen study. Those projects employing methods identify multiple proteins study the above lists acceptable require justification to why those proteins chosen, beyond fact they on eligible protein lists provided. Applications must also demonstrate adequate progress date the parent study. activities proposed the supplement must able be accomplished within current competitive segment. Award Project Period be eligible, parent award must active FY20 i.e., parent award received funds FY20 is in extension period), the research proposed the supplement should requested 1 year. earliest anticipated start date June 1, 2020. Budget Supplement budget requests cannot exceed 99,999 direct costs excluding subcontract F&A). Requests must reflect actual needs the proposed project. Requests be one year support only. Modular categorical budgets permitted. Eligible Individuals Program Director/Principal Investigator) Individual(s) must hold active grant cooperative agreement. supplements parent awards include multiple PDs/PIs, supplement be requested any all the PDs/PIs accordance the existing leadership plan) submitted the awardee institution the parent award Application Submission Information Applications this initiative must submitted using following opportunity its subsequent reissued equivalent. PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) instructions the SF424 R&R) Application Guide and PA-18-591 must followed, the following additions: Requests must received 5:00 PM local time applicant organization June 1, 2020 funding FY 2020. Application Due Date(s) – June 1, 2020, 5:00 PM local time applicant organization. funding consideration, applicants must include NOT-TR-20-008” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Requests be one year support only. be eligible, parent award must active FY20 i.e. applications a no-cost extension not eligible apply.). earliest anticipated start date June 1, 2020. Research Strategy section the application limited 6 pages. process Streamlined Submissions using eRA Commons cannot used this initiative. Applicants strongly encouraged notify program contact the Institute supporting parent award a request been submitted response this FOA order facilitate efficient processing the request. Supplement budget requests cannot exceed 99,999 direct costs excluding subcontract F&A) one year. Requests must reflect actual needs the proposed project. Modular categorical budgets permitted Individual(s) must hold active grant cooperative agreement. supplements parent awards include multiple PDs/PIs, supplement be requested any all the PDs/PIs accordance the existing leadership plan) submitted the awardee institution the parent award. Inquiries Please direct inquiries to: Karlie Sharma, Ph.D. National Center Advancing Translational Sciences NCATS) Telephone: 301-451-4965 Email: Karlie.Sharma@nih.gov  

Notice of Special Interest: Administrative Supplements for Existing NIH Countermeasures Against Chemical Threats (CounterACT) Program Research Grants and Cooperative Agreement Awards

Notice of Special Interest
Monday, January 6, 2020
Tuesday, August 4, 2020
333
NOT-NS-20-029

Funding Opportunity Purpose

Notice Special Interest: Administrative Supplements Existing NIH Countermeasures Against Chemical Threats CounterACT) Program Research Grants Cooperative Agreement Awards Notice Number: NOT-NS-20-029 Key Dates Release Date: January 6, 2020 First Available Due Date: August 03, 2020 Expiration Date: August 04, 2020 Related Announcements PA-18-591 NOT-NS-20-030 Issued National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) Purpose NIH inviting administrative supplement applications provide additional funds active CounterACT research grants cooperative agreement projects support activities such new collaborations pilot studies were unanticipated the time the new competing continuation application submitted. proposed activities must within original research scope the parent award. Supplemental funding includes direct costs well associated facilities administrative costs. supplement project start any time during budget period must end the last day the budget period. parent award not in terminal no-cost extension going a no-cost extension FY2020. Application budgets limited 75,000 total costs must reflect actual needs the proposed project. Only parent CounterACT research grant cooperative agreement awards funded through following FOAs any reissues these announcements) eligible request supplemental funding under NOSI: PAR-13-208: Countermeasures Against Chemical Threats CounterACT) Cooperative Research Projects U01) PAR-15-146; PAR-16-329; PAR-18-657: Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional) PAR-16-330: Countermeasures Against Chemical Threats CounterACT): Identification Therapeutic Lead Compounds U01 Clinical Trial Allowed) PAR-16-331: Countermeasures Against Chemical Threats CounterACT): Optimization Therapeutic Lead Compounds U01 Clinical Trial Optional) PAR-18-721: Countermeasures Against Chemical Threats CounterACT) Exploratory/Developmental Projects Translational Research R21 Clinical Trial Allowed) Scope Interest overall goal the NIH Countermeasures Against Chemical Threats CounterACT) program to support research development therapeutics can reduce mortality morbidity the event the release chemical threat agents. Chemical threat agents toxic compounds could released a deliberate terrorist attack against civilians, by accidental natural disaster causing mass casualties. include chemical warfare agents e.g., sarin, chlorine, sulfur mustard), toxic industrial chemicals e.g., cyanide, hydrogen sulfide, phosgene), pesticides e.g., parathion, brodifacoum), pharmaceutical-based agents e.g., opioids) other chemicals. Applications proposing research chemical threats are of interest the program not considered funding. research related opioid threats being proposed, NOT-NS-18-019 a description research supported the NIH CounterACT program. Examples topics interest include, are limited to: Facilitating collaborations fellow awardees within CounterACT community Identify and/or recruit new resources such investigators additional expertise, industry partner, research tools, systems, assays enhance outcomes the parent award Limited, pilot studies establish proof-of-principle approaches Investigators planning submit application response this NOSI strongly advised contact discuss proposed research/aims the Program Officer their parent CounterACT award well advance the receipt deadline better determine appropriateness relevance the supplement project Application Submission Information Applications this initiative must submitted using following opportunity its subsequent reissued equivalent. PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) instructions the SF424 R&R) Application Guide PA-18-591 must followed, the following additions Research Strategy part the application, summarize scope the parent supplemental projects describe proposed aims research strategy the new study. Clearly state the supplemental efforts fit the scope the parent award. research strategy should clearly demonstrate the new collaboration(s), resource(s), and/or studies benefit parent award why those otherwise be feasible either within currently funded efforts by rebudgeting funds. Applicants the program urged consider directly address elements rigor reproducibility described NOT-OD-15-103 their experimental design. Administrative Evaluation Criteria the proposed supplemental project outcomes relevant the NIH CounterACT program mission goals? the work proposed within scope the active parent award? Does proposed research/scientific team possess expertise conduct achieve goals the supplemental study? Does supplemental proposal include well-described, rigorous scientific approach? the project yield significant preliminary data support more advanced drug discovery development efforts? the scope budget reasonable the proposed studies? Letters Support Applicants must include letter appropriate institutional biosafety officials indicating studies deemed safe research personnel the environment. formal letter support must provided all newly proposed collaborative, consultative, and/or contract arrangements. Application Due Date(s) – August 3,2020, 5:00 PM local time applicant organization. funding consideration, applicants must include “NOT-NS-20-029” without quotation marks) the Agency Routing Identifier field box 4b) the SF424 R&R form. Applications without information box 4b not considered this initiative. Requests be one year support only. Research Strategy section the application limited 6 pages. Only existing awardees CounterACT program eligible apply. process Streamlined Submissions using eRA Commons cannot used this initiative. Applicants strongly encouraged notify CounterACT Program Officer the parent award a request been submitted response this FOA order facilitate efficient processing the request. application budget cannot exceed 75,000 total costs must reflect actual needs the project. Inquiries Please direct inquiries related the overall NIH CounterACT Program and/or parent awards managed the National Institutes Neurological Disorders Stroke NINDS) to: David A. Jett, PhD Telephone: 301-496-6035 Email: jettd@nih.gov Shardell M. Spriggs, PhD Telephone: 301-443-8189 Email: shardell.spriggs@nih.gov parent awards managed the National Institute Arthritis Musculoskeletal Skin Diseases NIAMS): Hung Tseng, Ph.D. Telephone: 301-594-5032 Email: tsengh@mail.nih.gov parent awards managed the National Eye Institute NEI): Houmam Araj, Ph.D. Telephone: 301-451-2020 Email: arajh@nei.nih.gov parent awards managed the National Institute Environmental Health Sciences NIEHS): Srikanth S. Nadadur, Ph.D. Telephone: 984-287-3296 Email: nadadurs@niehs.nih.gov parent awards managed the National Institute Drug Abuse NIDA): Kristopher Bough, Ph.D. Telephone: 301-443-9800 Email: boughk@nih.gov

Notice of Special Interest: Administrative Supplements to Promote and Expand into the Research and Development of Medical Countermeasures Against Chemical Threats

Notice of Special Interest
Monday, January 6, 2020
Tuesday, August 4, 2020
333
NOT-NS-20-030

Funding Opportunity Purpose

Notice Special Interest: Administrative Supplements Promote Expand the Research Development Medical Countermeasures Against Chemical Threats Notice Number: NOT-NS-20-030 Key Dates Release Date: January 6, 2020 First Available Due Date: February 03, 2020 Expiration Date: August 04, 2020 Related Announcements PA-18-591 NOT-NS-20-029 Issued National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) Purpose NIH inviting administrative supplement applications existing awards are currently focused developing medical countermeasures MCMs) against chemical threats allow to expand research focus this critical field. Supplemental funding includes direct costs well associated facilities administrative costs. supplement project start any time during budget period must end the last day the budget period. parent award not in terminal no-cost extension. Application budgets limited no than amount the current award 125,000 total costs whichever lower) must reflect actual needs the proposed project. Scope Interest overall goal the NIH Countermeasures Against Chemical Threats CounterACT) program to support research development therapeutics can reduce mortality morbidity the event the release chemical threat agents. Chemical threat agents toxic compounds could released a deliberate terrorist attack against civilians, by accidental natural disaster causing mass casualties. include chemical warfare agents e.g., sarin, chlorine, sulfur mustard), toxic industrial chemicals e.g., cyanide, hydrogen sulfide, phosgene), pesticides e.g., parathion, brodifacoum), pharmaceutical-based agents e.g., opioids) other chemicals. research related opioid threats being proposed, NOT-NS-18-019 a description research supported the NIH CounterACT program. scope research will supported this NOSI should consistent the following currently published funding opportunity announcements, PAR-18-721, PAR-19-030, PAR-19-040, including basic translational research through preclinical studies. view list currently funded projects, please visit our webpage, CounterACT Research Network Funded Investigators. Examples topics chemical agents interest include, are limited to: Pulmonary Agents Chlorine Phosgene): Development MCMs prevent treat lung damage including pulmonary edema fibrosis) resulting after exposure Pharmaceutical-based Agents Synthetic Opioids): Development MCMs treat life-threatening respiratory depression caused opioid intoxication. post-exposure treatments should quick-acting effective against variety opioids, e.g., fentanyl, carfentanil. NOT-NS-18-019 more details Vesicants Sulfur Mustard Lewisite): Development MCMs mitigate acute and/or long-term injuries resulting exposure the skin, eyes, mucous membranes vesicating agents. Specific areas interest include treating corneal neovascularization, fibrosis, mustard gas keratopathy. Cellular Respiration/Blood Agents Cyanide): Development MCMs treat acute poisoning. Antidotes should rapidly effective easily administered first responders Nerve Agents Organophosphorus OP) Pesticides: Development MCMs treat seizures either before after become refractory treatment benzodiazepines therapeutics promote neuronal survival other persistent effects after seizure termination. the federal monograph, Sarin: Potential Long-term Neurological Effects. are chemicals interest addition those listed above, Investigators planning submit application response this NOSI strongly advised contact discuss proposed research/aims the Program Officer their parent award the CounterACT Program Officer listed below) most relevant the supplement project well advance the receipt deadline determine responsiveness, programmatic interest, relevance. Applications propose research chemical threats are of interest the program not considered funding. Application Submission Information Applications this initiative must submitted using following opportunity its subsequent reissued equivalent. PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) instructions the SF424 R&R) Application Guide PA-18-591 must followed, the following additions Research Strategy part the application, include abstract the proposed research shows relevance developing chemical medical countermeasures. Summarize scope the parent supplemental projects describe proposed aims research strategy the new study. Clearly state the supplemental efforts fit the scope the parent grant. Applicants the program urged consider directly address elements rigor reproducibility described NOT-OD-15-103 their experimental design. Administrative Evaluation Criteria the proposed supplemental project outcomes relevant the NIH CounterACT program mission goals? the work proposed within scope the active parent award? Does proposed research/scientific team possess expertise conduct achieve goals the supplemental study? Does supplemental proposal include well-described, rigorous scientific approach? the project yield significant preliminary data support more advanced drug discovery development efforts? the scope budget reasonable the proposed studies Letters Support Applicants must include letter appropriate institutional biosafety officials indicating studies deemed safe research personnel the environment. formal letter support must also provided all newly proposed collaborative, consultative, and/or contract arrangements. Application Due Date(s) – February 3, 2020, April 1, 2020, June 1, 2020, August 3, 2020, 5:00 PM local time applicant organization. funding consideration, applicants must include NOT-NS-20-030” without quotation marks) the Agency Routing Identifier field box 4b) the SF424 R&R form. Applications without information box 4b not considered this initiative. Requests be one year support only. Research Strategy section the application limited 6 pages. process Streamlined Submissions using eRA Commons cannot used this initiative. Applicants strongly encouraged notify program contact the Institute supporting parent award the CounterACT Program Officer listed below) most relevant the supplemental project a request been submitted response this FOA order facilitate efficient processing the request. application budget cannot exceed 125,000 total costs. Inquiries Please direct inquiries related the overall NIH CounterACT Program, neurological injury metabolic/blood research to: David A. Jett, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-6035 Email: jettd@nih.gov Shardell M. Spriggs, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-443-8189 Email: shardell.spriggs@nih.gov questions related dermal/vesicant-induced injuries: Hung Tseng, Ph.D. National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Telephone: 301-594-5032 Email: tsengh@mail.nih.gov questions related ocular injury research: Houmam Araj, Ph.D. National Eye Institute NEI) Telephone: 301-451-2020 Email: arajh@nei.nih.gov questions related pulmonary injury research: Srikanth S. Nadadur, Ph.D. National Institute Environmental Health Sciences NIEHS) Telephone: 919-541-5327 Email: nadadurs@niehs.nih.gov questions related pharmaceutical based agents: Kristopher Bough, Ph.D. National Institute Drug Abuse NIDA) Telephone: 301-443-9800 Email: boughk@nih.gov

Notice of Special Interest: Countermeasures Against Chemical Threats (CounterACT) U54 Centers of Excellence will only support targeted chemical threats of interest

Notice of Special Interest
Monday, January 6, 2020
Thursday, September 10, 2020
U54
NOT-NS-20-031

Funding Opportunity Purpose

Notice Special Interest: Countermeasures Against Chemical Threats CounterACT) U54 Centers Excellence only support targeted chemical threats interest Notice Number: NOT-NS-20-031 Key Dates Release Date: 01/06/2020 First Available Due Date: September 09, 2020 Expiration Date: September 10, 2020 Related Announcements PAR-18-657 Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) Purpose NIH Countermeasures Against Chemical Threats CounterACT) program supports research development therapeutics can reduce mortality morbidity the event the release chemical threat agents. important component the CounterACT research network the U54 Research Centers Excellence. U54 Centers designed support three more projects scientific cores having unifying well-defined goal problem area research synergistically produce rigorous interdisciplinary research the highest quality. is expectation support interrelated projects collaborating investigators yield results beyond those achievable each project pursued separately without formal interaction among participating investigators. more information the CounterACT Program, please visit our website. view list currently funded projects, please visit our webpage, CounterACT Research Network Funded Investigators. NIH CounterACT program issuing NOSI provide chemical threat agents will supported grant applications the September 9, 2020 receipt date PAR-18-657 U54 Centers Excellence. only chemical agents will supported the U54 program are: Blood/Metabolic Agents: hydrogen cyanide, potassium cyanide sodium cyanide Organophosphorus OP) Chemical Warfare Agents Pesticides Opioids: carfentanil, fentanyl related analogs, NOT-NS-18-019 Pulmonary Agents: chlorine phosgene Vesicants: sulfur mustard lewisite Applicants strongly encouraged contact CounterACT Program Staff listed the parent funding opportunity announcement PAR-18-657) determine their proposed threat agent(s) of interest the NIH CounterACT program. Applications propose research chemical threats are listed above not considered funding. research related opioid threats being proposed, NOT-NS-18-019 a description research supported the NIH CounterACT program. Application Submission Information Submit applications this initiative using following funding opportunity announcement through expiration date this notice. PAR-18-657 - Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional) notice applies the September 9, 2020 due date PAR-18-657. instructions the SF424 R&R) Application Guide the funding opportunity announcement used submissionmust followed, the following additions funding consideration, applicants must include NOT-NS-20-031” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Applications nonresponsive terms this NOSI be be considered the NOSI initiative. Inquiries Please direct inquiries the Scientific/Research, Peer Review, Financial/Grants Management contacts Section VII the listed funding opportunity announcements.

Notice of New Budget Limitation for PAR-18-657 Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 Clinical Trial Optional).

NOT
Thursday, June 14, 2018
Sunday, January 1, 2023
NOT-NS-18-072

Funding Opportunity Purpose

Notice New Budget Limitation PAR-18-657 Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional). Notice Number: NOT-NS-18-072 Key Dates Release Date: June 14, 2018 Related Announcements PAR-18-657 Issued National Eye Institute NEI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to amend award budget PAR-18-657 Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional)." Section II. Award Information Currently Reads: Award Budget Application budgets not exceed 2.5 million direct costs per year. applications not need request maximum budget the size duration the awards vary because nature scope research programs vary. Modified Read: Award Budget Application budgets not exceed $2.0 million in direct costs per year. applications not need request maximum budget the size duration the awards vary because nature scope research programs vary. other aspects this FOA remain same. Inquiries Please direct inquiries to: David A. Jett, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone:  301-496-6035 Email: jettd@ninds.nih.gov

Notice of New Budget Limitation for PAR-16-331 Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01)

NOT
Tuesday, June 12, 2018
Sunday, January 1, 2023
NOT-NS-18-071

Funding Opportunity Purpose

Notice New Budget Limitation PAR-16-331 Countermeasures Against Chemical Threats CounterACT): Optimization Therapeutic Lead Compounds U01) Notice Number: NOT-NS-18-071 Key Dates Release Date: June 12, 2018 Related Announcements PAR-16-331 Issued National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) Purpose purpose this notice to amend award budget PAR-16-331 Countermeasures Against Chemical Threats CounterACT): Optimization Therapeutic Lead Compounds U01)." Section II. Award Information Currently Reads: Award Budget Application budgets not limited, need reflect actual needs the proposed project. most applications within scope this FOA, expected direct cost individual awards 300,000-$500,000 per year. applications not need request maximum budget the size duration the awards vary depending upon nature scope research programs. Modified Read: Award Budget Application Budget not exceed $500,000 in direct costs per year. applications not need request maximum budget the size duration the awards vary because nature scope research programs vary. other aspects this FOA remain same. Inquiries Please direct inquiries to: David A. Jett, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone:  301-496-6035 Email:  jettd@ninds.nih.gov nbsp;

Notice of Participation in PAR-18-721 "Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects in Translational Research (R21 Clinical Trial Not Allowed)

NOT
Thursday, March 29, 2018
Sunday, January 1, 2023
NOT-NS-18-053

Funding Opportunity Purpose

Notice Participation PAR-18-721 Countermeasures Against Chemical Threats CounterACT) Exploratory/Developmental Projects Translational Research R21 Clinical Trial Allowed) Notice Number: NOT-NS-18-053 Key Dates Release Date: March 29, 2018 Related Announcements PAR-18-721 Issued National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) Purpose purpose this Notice to inform potential applicants the National Eye Institute NEI),  National Institute Environmental Health Sciences NIEHS), the National Institute Drug Abuse NIDA) participating PAR-18-721 Countermeasures Against Chemical Threats CounterACT) Exploratory/Developmental Projects Translational Research R21 Clinical Trial Allowed). following sections been updated reflect participation NINDS this FOA. Currently Reads: Part 1. Overview Information Components Participating Organizations National Institute Neurological Disorders Stroke NINDS) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Catalog Federal Domestic Assistance CFDA) Number(s) 93.853; 93.846 Modified Read: Part 1. Overview Information Components Participating Organizations National Institute Neurological Disorders Stroke NINDS) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Eye Institute NEI) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS)   Catalog Federal Domestic Assistance CFDA) Number(s) 93.853; 93.846; 93.867; 93.279; 93.113 following contacts been added: Section VII. Agency Contacts Scientific/Research Contact(s) questions related ocular injury research:  Houmam Araj, Ph.D. National Eye Institute NEI) Telephone: 301-451-2020 Email: arajh@nei.nih.gov questions related pulmonary injury research: Srikanth S. Nadadur, Ph.D. National Institute Environmental Health Sciences NIEHS) Telephone: 919-541-5327 Email: nadadurs@niehs.nih.gov questions related pharmaceutical based agents: Kristopher Bough, Ph.D. National Institute Drug Abuse NIDA) Telephone: 301-443-9800 Email: boughk@nih.gov Financial/Grants Management Contact(s) Karen Robinson Smith National Eye Institute NEI) Telephone: 301-451-2020 Email: kyr@nei.nih.gov Lisa A. Edwards, MBA National Institute Environmental Health Sciences NIEHS) Telephone:  919-541-0751 E-mail: archer@niehs.nih.gov Amy Connolly National Institute Drug Abuse NIDA) Telephone: 301-827-4457 Email: connolla@mail.nih.gov other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Shardell Spriggs, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-443-8189 Email: shardell.spriggs@nih.gov

Countermeasures Against Chemical Threats (CounterACT): Opportunities in Opioid Research

NOT
Monday, November 27, 2017
Sunday, January 1, 2023
NOT-NS-18-019

Funding Opportunity Purpose

Countermeasures Against Chemical Threats CounterACT): Opportunities Opioid Research Notice Number: NOT-NS-18-019 Key Dates Release Date: November 27, 2017 Related Announcements PAR-15-315 PAR-16-330 PAR-16-331 Issued National Institute Neurological Disorders Stroke NINDS) National Institute Drug Abuse NIDA) Purpose purpose this notice to highlight NIH/NINDS Countermeasures Against Chemical Threats CounterACT) program's interest developing safe effective therapeutics would prevent morbidity mortality following exposure the opioids fentanyl, carfentanil, acetylfentanyl, alfentanil, and/or diacetylmorphine heroin). program concentrates developing therapeutics treat and/or prevent injuries deaths may result exposure chemical threats a variety scenarios. Applications being accepted under three specific Funding Opportuntiy Announcements FOAs) issued the NIH CounterACT program PAR-15-315, PAR-16-330, PAR-16-331). be considered appropriate these FOAs, applications must follow instructions general descriptions found these FOAs well the following requirements related the specialized mission the NIH CounterACT program. Research supported these FOAs must relevant chemical emergencies where general civilian population might exposed opioids. research might include industrial accidents, natural disasters causing casualties, deliberate attacks again civilians. examples research could supported include, are limited to, following: Safety efficacy studies naloxone other FDA-approved drugs use against opioids listed above, especially they relate potential respiratory problems Safety efficacy studies naloxone other FDA-approved drugs use against opioids listed above these opioids administered a method consistent a deliberate attack against civilians, by industrial accidents natural disasters causing mass casualties e.g. aerosolized, food water, etc.) opioid overdose antidotes greater safety efficacy naloxone other FDA- approved drugs match higher potency fentanyl analogues, including naloxone-related antidotes those based new therapeutic targets Antidotes longer half-lives that multiple doses not needed rapid succession, many people be treated once during mass casualty event; includes increases serum half-life well alteration degradative metabolism Single antidotes acceptable activity against least or of opioids listed above NIH CounterACT program support exploratory developmental research PAR-15-315) well the identification PAR-16-330) optimization PAR-16-331) therapeutic lead compounds. Potential applicants should the descriptions scientific scope found these FOAs. Applicants strongly urged contact NIH representatives listed below prior submission. Inquiries Please direct general NIH CounterACT inquiries to: David A. Jett, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-6035 Email: david.jett@nih.gov Please direct specific opioid research inquiries: Kristopher J. Bough, Ph.D. National Institute Drug Abuse NIDA) Telephone: 301-443-9800 Email: boughk@nih.gov nbsp;

Notice of Intent to Publish a Funding Opportunity Announcement for Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54)

NOT
Tuesday, September 19, 2017
Sunday, January 1, 2023
NOT-NS-18-009
David A. Jett

Funding Opportunity Purpose

Notice Intent Publish Funding Opportunity Announcement Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54) Notice Number: NOT-NS-18-009 Key Dates Release Date: September 19, 2017 Estimated Publication Date Announcement: December 2017  First Estimated Application Due Date: September 2018 Earliest Estimated Award Date: July 2019  Earliest Estimated Start Date: July 2019  Related Announcements None Issued National Institute Neurological Disorders Stroke NINDS) Purpose National Institute Neurological Disorders Stroke NINDS), intends re-issue Program Announcement Special Review Considerations PAR) solicit applications quot;Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54)". goal this initiative to provide support translational research develop therapeutics reducing mortality morbidity caused acute exposures chemical threat agents. Chemical threats toxic chemicals could used a terrorist attack accidentally released industrial production, storage shipping.  scope the research includes target candidate identification characterization, through candidate optimization demonstration in vivo efficacy consistent the product's intended in humans. applicants submitting U54 renewal applications, research under FOA should culminate an optimized lead compound ready advanced development.  www.ninds.nih.gov/counteract a description the NIH CounterACT research program. Notice being provided allow potential applicants sufficient time develop meaningful collaborations responsive projects.  general description the planned FOA provided below. sure follow guidance specific instructions the final published FOA once is released.  Research Initiative Details planned FOA encourage collaborative multidisciplinary investigations, combining expertise toxicology drug discovery development, discover develop new improved therapeutics treating victims acute chemical exposures. NIH CounterACT research program utilize Specialized Center Cooperative Agreements U54) support Research Centers Excellence up 5 years.  Center include several individual research projects scientific administrative cores create interdisciplinary multifaceted research approach. should a unifying well-defined goal problem area research which project relates contributes, thereby producing synergistic research environment allows research effort share resources creative strengths the others. is expectation support inter-related projects collaborating investigators yield results beyond those achievable each project pursued separately without formal interaction among participating investigators. civilian chemical threat spectrum includes chemical warfare agents e.g., sarin), toxic industrial chemicals e.g., cyanide), pesticides e.g., parathion), other chemicals.  agents included the current Department Homeland Security DHS) Chemical Terrorism Risk Assessment CTRA) list, is USG official only will be included the planned FOA.  Therefore, applicants strongly urged contact Scientific/Research staff listed this Notice determine their proposed threat agent(s) of interest the NIH.    Research Center must establish milestones include discrete quantitative goals create or no-go decision points the project. APPLICATIONS NOT BEING SOLICITED THIS TIME. Inquiries Please direct inquiries to: David A. Jett, Ph.D. National Institute Neurological Disorders Stroke, NINDS Telephone: 301-496-6035 Email: jettd@ninds.nih.gov

Notice of NIDA's Participation in PAR-16-331 "Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01)"

NOT
Monday, July 17, 2017
Friday, January 1, 2021
NOT-DA-17-048

Funding Opportunity Purpose

The purpose of this Notice is to inform potential applicants that the National Institute on Drug Abuse (NIDA) will participate, effective immediately, in the Funding Opportunity Announcement (FOA) PAR-16-330 "Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01)".

Pages